ReviewNature reviews. Drug discovery2010
Personalized medicine in oncology: the future is now.
Review in Nature reviews. Drug discovery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.PharmacoEconomics · 2013Pooled it
- A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.Investigational new drugs · 2012Trial
- Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Trial
- Hydrogel-Nanoparticle Bioactive Platforms for Post-Surgical Prevention of Tumor Recurrence.Nanomaterials (Basel, Switzerland) · 2026Review
- Battlegrounds of treatment resistance: decoding the tumor microenvironment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Polymeric Nanoparticles for Targeted Lung Cancer Treatment: Review and Perspectives.Pharmaceutics · 2025Review
- Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies.Cancers · 2025Article
- Toward Personalized Immunotherapeutic Drug Monitoring with Multiplexed Extended-Gate Field-Effect-Transistor Biosensors.Small science · 2025Article
- Multimodal identification of the mouse brain using simultaneous CaCommunications biology · 2025Article
- Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance.Cells · 2025Review
- Biomarker understanding first lessons from drug development for IgA-driven autoimmune and fibrotic diseases.Cambridge prisms. Precision medicine · 2025Review
- Establishment and characterization of primary epithelial cell cultures from healthy canine mammary gland tissue.Frontiers in veterinary science · 2025Article
- Cancer cachexia: biomarkers and the influence of age.Molecular oncology · 2024Review
- LUNGBANK: a novel biorepository strategy tailored for comprehensive multiomics analysis and P-medicine applications in lung cancer.Turkish journal of biology = Turk biyoloji dergisi · 2024Article
- Potential of CDC25 phosphatases in cancer research and treatment: key to precision medicine.Frontiers in pharmacology · 2024Review
- Learning Individual Survival Models from PanCancer Whole Transcriptome Data.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure.Pharmaceutics · 2023Article
- Flow Cytometry Detection of Anthracycline-Treated Breast Cancer Cells: An Optimized Protocol.Current issues in molecular biology · 2022Article
- Need for numbers: assessing cancer survivors' needs for personalized and generic statistical information.BMC medical informatics and decision making · 2022Article
- Identifying network biomarkers of cancer by sample-specific differential network.BMC bioinformatics · 2022Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer chemotherapy is in evolution from non-specific cytotoxic drugs that damage both tumour and normal cells to more specific agents and immunotherapy approaches. Targeted agents are directed at unique molecular features of cancer cells, and immunotherapeutics modulate the tumour immune response; both approaches aim to produce greater effectiveness with less toxicity. The development and use of such agents in biomarker-defined populations enables a more personalized approach to cancer treatment than previously possible and has the potential to reduce the cost of cancer care.
Indexed as
Identifiers
20431568What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.